Scholarlink

Introduction <p>Respiratory syncytial virus (RSV) manifesting as lower respiratory tract illness (LRTI; RSV-LRTI) has a significant clinical and economic impact for infants in the Kingdom of Saudi Arabia (KSA) and globally. We evaluated the budget impact (BI) of strategies involving maternal vaccine (RSVpreF) and single-dose monoclonal antibody (nirsevimab) to protect KSA infants against RSV-LRTI.</p> Methods <p>A deterministic cohort model evaluated the clinical and economic burden of RSV-LRTI and the impact of interventions among five annual birth cohorts of infants aged &lt; 1&#xa0;year. Parameter values were estimated on the basis of published sources using KSA-specific data to the extent possible. Model outcomes included RSV-LRTI episodes (hospital, emergency department [ED], primary care [PC]), disease-attributable deaths, medical care costs, and intervention costs (in US$). Nirsevimab alone (herein “Nirs”; price: $1005.78; uptake: 90%) and, alternatively, mixed approach RSVpreF (price: $217.07; uptake: 14.3%) with nirsevimab (uptake: 90%) for unprotected infants (“MV + Nirs”) were compared against no intervention (“NoInt”).</p> Results <p>NoInt would yield 2,115,924 cases (hospital: 85,898, ED: 943,770, PC: 1,086,255) and $817.9 million in medical care costs. Nirs would prevent 1,206,819 cases and $470.1 million in medical care costs; with $2054.3 million in intervention costs, BI would be $1.6 billion. Compared with NoInt, MV + Nirs would prevent 1,143,754 cases and $457.1 million in medical care costs; with $1851.6 million in intervention costs (MV: $78.6, Nirs: $1773.0), BI would be $1.4 billion.</p> Conclusions <p>Findings suggest that either strategy would substantially reduce the burden of RSV-LRTI. Even with low uptake, adding RSVpreF (mixed approach) yielded considerably lower budget impact compared with nirsevimab alone.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月17日

查看全文
  • Adel S. Alharbi,
  • Nada Abu-Shraie,
  • Hana Al Abdulkarim,
  • Ibtisam H. Alharbi,
  • Ahuva Averin,
  • Amy W. Law,
  • Diana Mendes,
  • Erin Quinn,
  • Mostafa Zayed,
  • Ayman Behiry,
  • Hammam Haridy,
  • Mostafa Mousa

摘要

Introduction

Respiratory syncytial virus (RSV) manifesting as lower respiratory tract illness (LRTI; RSV-LRTI) has a significant clinical and economic impact for infants in the Kingdom of Saudi Arabia (KSA) and globally. We evaluated the budget impact (BI) of strategies involving maternal vaccine (RSVpreF) and single-dose monoclonal antibody (nirsevimab) to protect KSA infants against RSV-LRTI.

Methods

A deterministic cohort model evaluated the clinical and economic burden of RSV-LRTI and the impact of interventions among five annual birth cohorts of infants aged < 1 year. Parameter values were estimated on the basis of published sources using KSA-specific data to the extent possible. Model outcomes included RSV-LRTI episodes (hospital, emergency department [ED], primary care [PC]), disease-attributable deaths, medical care costs, and intervention costs (in US$). Nirsevimab alone (herein “Nirs”; price: $1005.78; uptake: 90%) and, alternatively, mixed approach RSVpreF (price: $217.07; uptake: 14.3%) with nirsevimab (uptake: 90%) for unprotected infants (“MV + Nirs”) were compared against no intervention (“NoInt”).

Results

NoInt would yield 2,115,924 cases (hospital: 85,898, ED: 943,770, PC: 1,086,255) and $817.9 million in medical care costs. Nirs would prevent 1,206,819 cases and $470.1 million in medical care costs; with $2054.3 million in intervention costs, BI would be $1.6 billion. Compared with NoInt, MV + Nirs would prevent 1,143,754 cases and $457.1 million in medical care costs; with $1851.6 million in intervention costs (MV: $78.6, Nirs: $1773.0), BI would be $1.4 billion.

Conclusions

Findings suggest that either strategy would substantially reduce the burden of RSV-LRTI. Even with low uptake, adding RSVpreF (mixed approach) yielded considerably lower budget impact compared with nirsevimab alone.